ClinicalTrials.gg
RecruitingNCT07006493REFINE-HCMUpdated Dec 15, 2025

REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy

An interventional study of Transcatheter Intramyocardial Septal Radiofrequency Ablation System in Hypertrophic Cardiomyopathy, Obstructive, sponsored by SuZhou Sinus Medical Technologies Co.,Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by SuZhou Sinus Medical Technologies Co.,Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Cardiomyopathy, Hypertrophic with a site in China — 31 open to participants now, 44 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.

Planned enrollment
16th of 40
124 · median 83
Started
2025
with 10 others
No phase
20 of 72
12 open now
Primary completion
2026-12
later than 28 of 43 live
Registered
57th of 72
by date

Among the 72 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 16th largest by planned enrollment of the 40 interventional ones that give a count, is one of 11 that started in 2025, is one of 20 with no phase, reaches primary completion later than 28 of the 43 other live ones, and was the 57th registered.

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

31 of the 72 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Cardiomyopathy, Hypertrophic with a site in China, or all of them as a file.
02

Study summary

This is a prospective, multicenter, randomized, parallel-controlled, superiority clinical trial designed to evaluate the efficacy and safety of a transcatheter intramyocardial septal radiofrequency ablation system for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM). Eligible participants will be randomized in a 2:1 ratio to receive either active ablation under intracardiac echocardiographic guidance or a sham procedure. All participants will continue to receive standard-of-care medical therapy during the study period. The primary endpoint is the treatment effectiveness rate at 6 months, defined as a ≥50% reduction in LVOT gradient from baseline or a resting LVOT gradient \<30 mmHg.

03

Conditions studied

  • Hypertrophic Cardiomyopathy, Obstructive
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80 years, regardless of sex
  • Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM)
  • Presence of significant symptoms (e.g., dyspnea, chest pain, fatigue, palpitations, syncope)
  • class II or higher with LVOTG ≥50 mmHg at rest or provoked (assessed by echocardiography)
  • Septal thickness ≥15 mm
  • Unsuitable for surgical myectomy or refusal of surgery
  • Provided and agree to complete follow-up

Exclusion criteria

Exclusion Criteria:

  • Asymptomatic or non-obstructive HCM
  • Septal thickness ≥30 mm
  • Mitral valve anatomy not suitable for ablation as judged by investigator
  • High risk of sudden cardiac death (SCD) requiring ICD implantation
  • Complete right bundle branch block at screening
  • Infective endocarditis, myocarditis, atrial myxoma, or intracardiac thrombus
  • to transseptal access (e.g., septal patch)
  • Mechanical valves or history of aortic valve replacement
  • Severe heart failure with persistent symptoms and \<40%
  • Major cardiac events within 6 months (e.g., cardiac arrest, MI, heart failure hospitalization)
  • Significant structural heart disease requiring surgery
  • Prior septal reduction therapy or pacemaker implantation
  • Constrictive pericarditis or significant congenital heart disease
  • Bleeding disorders or contraindication to antithrombotic therapy
  • Liver dysfunction (/AST >3× )
  • Renal insufficiency (creatinine >2.0 mg/dL or on dialysis)
  • Pregnant, breastfeeding, or planning pregnancy within 6 months post-op
  • \<12 months
  • Participation in other studies within 30 days or 5 half-lives
  • Investigator determines poor compliance or unsuitability
  • Contraindications to cardiac MRI (e.g., ICD, allergy to contrast, claustrophobia)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Septal RF Ablation Group

    Participants in this group will receive a transcatheter intramyocardial septal radiofrequency ablation under intracardiac echocardiography (ICE) guidance using the investigational device system. Standardized pharmacological therapy will be continued throughout the study period.

    Device: Transcatheter Intramyocardial Septal Radiofrequency Ablation System

  • Sham comparator
    Sham Procedure (No RF Ablation)

    Participants in this group will undergo a sham procedure under ICE guidance. The catheter will be inserted but no ablation will be performed. Participants will continue standardized pharmacological therapy throughout the study period. After completion of the 6-month follow-up, participants in this arm may voluntarily choose to receive the investigational treatment.

    Device: Transcatheter Intramyocardial Septal Radiofrequency Ablation System

Interventions

  • DeviceTranscatheter Intramyocardial Septal Radiofrequency Ablation System

    The device system includes a single-use RF ablation catheter, sheath, RF generator, and irrigation pump. Ablation is guided by intracardiac echocardiography (ICE).

06

What researchers measure

Primary outcomes

  1. Treatment Effectiveness Rate at 6 Months

    Defined as either (1) a ≥50% reduction in resting LVOT gradient from baseline, or (2) resting LVOT gradient \<30 mmHg.

    Time frame: 6 months post-procedure

Secondary outcomes

  1. Change in Resting LVOT Gradient

    Measured by echocardiography at baseline, 6 months, and 12 months

    Time frame: Baseline, 6 months, 12 months

  2. Change in NYHA Functional Class

    Proportion of patients with improvement of ≥1 NYHA class

    Time frame: Baseline, 6 months, 12 months

  3. Change in 6-Minute Walk Distance

    Distance walked in 6 minutes, compared to baseline

    Time frame: Baseline, 6 months, 12 months

  4. Change in 12-Item Short Form Health Survey (SF-12) Score

    The SF-12 Health Survey includes two components: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Scores range from 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline, 6 months, 12 months

  5. Device Success Rate

    Defined as successful completion of RF ablation per protocol

    Time frame: Day of procedure

  6. Incidence of Adverse Events

    All adverse events related to device or procedure

    Time frame: Through 12 months

07

Study locations

2 of 2 sites recruiting
  • Capital Medical University Affiliated Beijing Anzhen Hospital
    Beijing, Beijing Municipality 100029, China
    Recruiting
  • Sir Run Run Shaw hospital
    Hangzhou, Zhejiang 310016, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual participant data (IPD) for this study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 52 interventional studies with no phase under Cardiomyopathy, Hypertrophic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 5, 2025
StartActual
Jul 20, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2027
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07006493
Lead sponsor
SuZhou Sinus Medical Technologies Co.,Ltd
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Jul 20, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Dec 15, 2025

Study contacts

Yongxin Su
Contact
suyongxin@sinusmedtech.com
+86 18121015668
Changshen Ma, Doctor
principal investigator · Capital Medical University Affiliated Beijing Anzhen Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion